Uncategorized Archives - Page 45 of 87 - PsychedelicNewsWire (PNW)

TuesdayFeb 23, 2021 12:15 pm

Researchers to Investigate Whether DMT Can Accelerate Recovery from Stroke

Algernon Pharmaceuticals, a Canadian company, plans to conduct a clinical trial to study how DMT, a psychedelic drug, can be used to trigger faster recovery in people who have had a stroke. The company says that study participants will receive a “microdose,” or an amount too small to trigger the hallucinogenic effects of the drug. While this small dose is too small for subjects to “trip,” it is hoped that the small dose will be sufficient to boost the recovery of neural activity and connections within the brain, thereby reducing how much damage the brain could suffer during and after…

MondayFeb 22, 2021 12:30 pm

How Psychedelics Are Helping Advance Modern Technology

In the 1950s, Oscar Janiger, a psychiatrist interested in LSD’s effect on creativity, dosed more than 950 individuals with the drug in his LA home. He carefully wrote down each individual’s experience and concluded at the end of his experiment that LSD could affect individuals who were already creative but could not make noncreative individuals more creative. He recognized that while LSD couldn’t inspire an individual who wasn’t creative to suddenly begin writing poetry or painting, it did provide creative individuals insights into their craft’s nature. Another researcher who was immensely interested in LSD, a chemist by the name of…

MondayFeb 22, 2021 12:17 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) Closer to Pure Mushrooms Sales with Company Code, NPN Submission

PULL recently received Company Code from Canada’s Natural and Non-prescription Health Products Directorate Code allows PULL to submit application to sell its first functional mushroom product Company intends to submit additional NPN applications during 2021 as part of larger strategy to develop portfolio of functional mushroom wellness products Functional mushrooms, those that provide a health benefit beyond just nutrition, are growing in popularity worldwide amid an accelerating trend to fend off viruses with immune-boosting food and drinks. Looking to seize part of a global functional mushroom market forecast by Data Bridge Market Research to hit $555.9 billion by 2028, Pure…

FridayFeb 19, 2021 1:15 pm

New Texas Legislation Will Allow State to Study MDMA, Psilocybin as Potential Treatments for Depression and PTSD

Last week, a legislator from Texas introduced a measure that would require the state to look into the therapeutic possibilities that ketamine, MDMA and psilocybin possess, which could help treat various mental health disorders.The bill, introduced by Rep. Alex Dominguez, would order that the Department of State Health in collaboration with the Texas Medical Board Services carry out the study and present their findings by Dec. 1, 2022. The bill, HB 1802, states that the researchers should assess and establish whether alternative therapies are successful in treating various mental health conditions such as chronic migraines and pain, bipolar disorder, post-traumatic…

ThursdayFeb 18, 2021 2:30 pm

Massachusetts General Hospital to Study How Psychedelics Influence the Brain

Massachusetts General Hospital is partnering with Atai Life Sciences to study the effects of psychedelics on the human brain. Atai Life Sciences is a biotech firm focused on developing medications to manage schizophrenia while also working on creating alternative treatments for various mental health conditions such as anxiety and depression. The two organizations decided to work together after the hospital set up a program, named the Center for Neuroscience of Psychedelics, to study psychedelic therapy. A psychiatric at the hospital, Jerrold Rosenbaum is the head of the program and has specialized in the treatment of psychiatric disorders. Rosenbaum stated that…

ThursdayFeb 18, 2021 10:01 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters Large Cannabis Biomass Agreements to Scale Up Extract Production, Announces DTC Eligibility of Common Shares in the U.S.

Pure Extracts entered into two large biomass purchase agreements, plans to ramp up production of high-potency THC and CBD extracts in 2021 Company expects historically low biomass purchase price will produce $590,000 revenue Company recently announced DTC eligibility of common shares for increased settlement and clearance speeds, wider access to brokerage firms Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company that focuses on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelics sector, recently entered into two substantial cannabis biomass purchase agreements (https://ibn.fm/Vbyxp) in addition to announcing that its common shares are now eligible for…

WednesdayFeb 17, 2021 2:45 pm

How Past Stigma and Recreational Use Are Slowing Psychedelic Science

According to recent research conducted in America that involved 952 individuals, psychedelic researchers who admitted to using psychedelic substances are often viewed by their abstinent counterparts as having less integrity. The study, which was reported in the “Public Understanding of Science” journal, proposes that stereotypes about both psychedelics and the individuals who use them may affect an individual’s view of researchers. University of Zurich’s Matthias Forstmann, who is the one of the authors of the study, stated that the personal use of these substances by the scientists studying them was a common occurrence, although very few researchers were open about…

TuesdayFeb 16, 2021 2:14 pm

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Delineates Parameters and Timeline of Study into Psilocybin-Based Active Treatments

Pure Extract Technologies pursues study into psilocybin active treatments Study to extend for 250-day period, targeting a number of milestones The study is set to be carried out at Toronto Institute of Pharmaceutical Technology, will be supervised by Pure Extracts’ scientific advisor, Dr. Alexander MacGregor Oregon recently voted to legalize psilocybin mushrooms for therapeutic use, a potential legislative movement which may soon be replicated in other jurisdictions Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, and functional mushroom sectors, has provided investors with an update in regards to its ongoing…

TuesdayFeb 16, 2021 1:30 pm

Cambridge City Councilors Approve Psychedelics Decriminalization Measure

A Massachusetts city may soon be decriminalizing the possession and use of most psychedelics and entheogenic plants. City councilors in Cambridge, Massachusetts, recently approved the policy order, which will also decriminalize all controlled substances. The order was sponsored by Councilor Jivan Sobrinho-Wheeler. Wheeler stated that research had shown that psychedelic fungi and plants, such as psilocybin mushrooms, could be used to treat various substance use and mental health issues. The initiative directed the manager of Cambridge City to cooperate with state and federal partners to decriminalize psychedelics, which are currently classified as controlled substances, in addition to being illegal under…

FridayFeb 12, 2021 11:00 am

New Jersey Gov Signs Bill Reclassifying Psilocybin

Gov. Phil Murphy of New Jersey recently signed a psilocybin reform measure that reclassified possession of up to one ounce of psilocybin mushrooms under a disorderly persons’ offense. This reclassification means that persons caught with small amounts of psilocybin will be subject to up to six months in jail, a $1000 fine or both. The offense was previously punishable with fines of up to $15 000 and a penalty of three to five years in jail, and was considered a third-degree crime. This change puts psilocybin mushroom possession in the state on par with resisting arrest, shoplifting, harassment or simple…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized